SI-BONE, Inc.
SIBNHealthcareNASDAQMedical Devices
Scan Results
Daily timeframePart of the healthcare sector, SI-BONE, Inc. (SIBN) is listed under Medical Devices. At a $829.1M market cap, SI-BONE, Inc. ranks as a small-cap company within healthcare. It offers a series of patented titanium implants and the instruments used to implant them, as well as implantable bone products.
Market Cap
$829.1M
Beta
0.70
P/E (TTM)
—
P/E (Fwd)
-55.92
EPS (TTM)
$-0.33
EPS (Fwd)
$-0.33
ROE
-8.3%
ROA
-4.6%
Cash
$145.9M
Total Debt
$42.8M
Free CF
-$861,875
52W Change
15.3%
Annual Financials
Cash vs Debt
Where SIBN stands vs its 150-day and 200-day moving averages
As of the August 31, 2026 close, SIBN finished 24.02% above its 150-day moving average ($15.49) and 17.35% above its 200-day moving average ($16.37). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is SIBN overbought or oversold?
At the August 31, 2026 close, SIBN's RSI(14) was 55.1, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $145.9M in cash comfortably exceeding the $42.8M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company is burning cash, with free cash flow at -$862K. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -8.3% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has grown from $90.2M (2021) to $200.9M (2025), reflecting a 123% increase over the period.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. No single metric tells the full story. Reviewing SIBN's risk profile alongside its fundamentals and technical indicators provides a more complete picture.